Vanguard Group Inc. Purchases 458,143 Shares of Amicus Therapeutics, Inc. (NASDAQ:FOLD)

Vanguard Group Inc. lifted its position in shares of Amicus Therapeutics, Inc. (NASDAQ:FOLD) by 1.6% during the 4th quarter, Holdings Channel reports. The firm owned 29,258,963 shares of the biopharmaceutical company’s stock after purchasing an additional 458,143 shares during the quarter. Vanguard Group Inc. owned about 0.10% of Amicus Therapeutics worth $275,619,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other institutional investors and hedge funds also recently modified their holdings of the company. Wellington Management Group LLP lifted its holdings in Amicus Therapeutics by 13.5% during the 3rd quarter. Wellington Management Group LLP now owns 23,964,044 shares of the biopharmaceutical company’s stock valued at $255,936,000 after purchasing an additional 2,856,101 shares during the last quarter. Point72 Asset Management L.P. bought a new position in shares of Amicus Therapeutics in the third quarter valued at about $13,530,000. Rice Hall James & Associates LLC lifted its stake in shares of Amicus Therapeutics by 41.0% during the 4th quarter. Rice Hall James & Associates LLC now owns 1,371,080 shares of the biopharmaceutical company’s stock worth $12,916,000 after buying an additional 398,942 shares during the last quarter. Old West Investment Management LLC boosted its holdings in shares of Amicus Therapeutics by 617.2% during the 3rd quarter. Old West Investment Management LLC now owns 340,441 shares of the biopharmaceutical company’s stock worth $3,636,000 after buying an additional 292,976 shares during the period. Finally, Peregrine Capital Management LLC boosted its holdings in shares of Amicus Therapeutics by 18.2% during the 4th quarter. Peregrine Capital Management LLC now owns 880,517 shares of the biopharmaceutical company’s stock worth $8,294,000 after buying an additional 135,716 shares during the period.

Amicus Therapeutics Stock Down 6.3 %

Shares of NASDAQ:FOLD opened at $7.50 on Friday. Amicus Therapeutics, Inc. has a 52-week low of $7.39 and a 52-week high of $12.65. The company has a market capitalization of $2.30 billion, a PE ratio of -41.67, a price-to-earnings-growth ratio of 1.51 and a beta of 0.69. The company has a debt-to-equity ratio of 2.01, a quick ratio of 2.42 and a current ratio of 3.39. The company has a fifty day moving average of $9.12 and a 200-day moving average of $9.86.

Wall Street Analysts Forecast Growth

Several equities research analysts have issued reports on FOLD shares. Morgan Stanley restated an “equal weight” rating and set a $12.00 price objective (down from $17.00) on shares of Amicus Therapeutics in a research report on Friday, December 13th. Needham & Company LLC reissued a “hold” rating on shares of Amicus Therapeutics in a report on Thursday, February 20th. Wells Fargo & Company decreased their price objective on Amicus Therapeutics from $18.00 to $17.00 and set an “overweight” rating on the stock in a report on Thursday, February 20th. Cantor Fitzgerald reissued an “overweight” rating and set a $21.00 target price on shares of Amicus Therapeutics in a report on Wednesday, January 15th. Finally, StockNews.com cut Amicus Therapeutics from a “buy” rating to a “hold” rating in a research report on Thursday, February 20th. Three analysts have rated the stock with a hold rating and seven have issued a buy rating to the company’s stock. According to MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average target price of $16.75.

Amicus Therapeutics Company Profile

Amicus Therapeutics, Inc, a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant; and Pombiliti + Opfolda, for the treatment of late onset.